ArticleNeurology2018
Neurogranin as a predictor of memory and executive function decline in MCI patients.
Open access · bronzeAbstract read
In one paragraph
Article in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 4 pooled it
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Neuropsychological Diagnostic Tools in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.Aging and disease · 2025Pooled it
- Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review.The European journal of neuroscience · 2022Pooled it
- Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.Translational psychiatry · 2020Pooled it
- Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026Article
- Synaptic protein CSF levels relate to memory scores in individuals without dementia.Alzheimer's research & therapy · 2025Article
- The Diagnostic Value of Cerebrospinal Fluid Neurogranin in Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Viral-mediated increased hippocampal neurogranin modulate synapses at one month in a rat model of controlled cortical impact.Scientific reports · 2024Article
- CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis.Alzheimer's research & therapy · 2024Article
- Synaptic protein CSF levels relate to memory scores in individuals without dementia.Research square · 2024Article
- Potential Application of MicroRNAs and Some Other Molecular Biomarkers in Alzheimer's Disease.Current issues in molecular biology · 2024Review
- Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.Neurology · 2023Article
- Neurogranin as an important regulator in swimming training to improve the spatial memory dysfunction of mice with chronic cerebral hypoperfusion.Journal of sport and health science · 2023Article
- Article
- Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.Diagnostics (Basel, Switzerland) · 2022Review
- Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnestic Subtypes of Mild Cognitive Impairment.Frontiers in aging neuroscience · 2022Article
- Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- ACells · 2021Review
- Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study.Neurology · 2021Article
- Decreased nesting behavior, selective increases in locomotor activity in a novel environment, and paradoxically increased open arm exploration in Neurogranin knockout mice.Neuropsychopharmacology reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Alison HeadleyFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Andres De Leon-BenedettiFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Chuanhui DongFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Bonnie LevinFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
David LoewensteinFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Christian CamargoFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Tatjana RundekFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Henrik ZetterbergFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Kaj BlennowFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Clinton B WrightFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD.
Xiaoyan SunFrom the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square; UK Dementia Research Institute (H.Z.), London; and National Institute of Neurological Disorders and Stroke (C.B.W.), Bethesda, MD. XXS356@med.miami.edu.
Alzheimer's Disease Neuroimaging Initiative
UK Dementia Research Institute · GBUniversity of California, San Diego · USUniversity College London · GBNational Hospital for Neurology and Neurosurgery · GBNational Institute of Neurological Disorders and Stroke · USUniversity of Gothenburg · SE
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MMiami Clinical and Translational Science InstituteUL1TR002736 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI CARRASQUILLO, OLVEEN, KOBETZ, ERIN N · 2018 to 2022
$23.2MNIA NIH HHS U01 AG024904
Abstract
objectiveTo determine whether high CSF levels of neurogranin (Ng) predict longitudinal decline in memory and executive function during early-stage Alzheimer disease (AD).
methodsBaseline levels of CSF Ng were studied in relation to cross-sectional and longitudinal cognitive performance over 8 years. Data were obtained from the Alzheimer's Disease Neuroimaging Initiative database, and participants with normal cognition (n = 111) and mild cognitive impairment (MCI) (n = 193) were included.
resultsHigh levels of CSF Ng were associated with poor baseline memory scores (β = -0.21,
conclusionsHigh CSF Ng associates with poor memory scores in participants with MCI cross-sectionally and with poor memory and executive function longitudinally. The association of Ng with cognitive measures disappears when tau and Aβ
Indexed as
AgedAged, 80 and overAmyloid beta-PeptidesApolipoproteins EChi-Square DistributionCognitive DysfunctionCross-Sectional StudiesExecutive FunctionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMemory DisordersMiddle AgedNeurograninAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoproteins ENeurograninPeptide Fragmentstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.